Cargando…

Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab

BACKGROUND & AIMS: Radiological progression patterns to first‐line sorafenib have been associated with post‐progression and overall survival in advanced hepatocellular carcinoma, but these associations remain unknown for therapies in second‐ and later‐line settings. This post hoc analysis of REA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reig, Maria, Galle, Peter R., Kudo, Masatoshi, Finn, Richard, Llovet, Josep M., Metti, Andrea L., Schelman, William R., Liang, Kun, Wang, Chunxiao, Widau, Ryan C., Abada, Paolo, Zhu, Andrew X.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Liver Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898500/ https://www.ncbi.nlm.nih.gov/pubmed/33188713 http://dx.doi.org/10.1111/liv.14731

Ejemplares similares

Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
por: Zhu, Andrew X., et al.
Publicado: (2021)

Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials
por: Llovet, Josep M., et al.
Publicado: (2022)

Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non–Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2
por: Finn, Richard S, et al.
Publicado: (2022)

Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials
por: Zhu, Andrew X, et al.
Publicado: (2020)

Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2
por: Kudo, Masatoshi, et al.
Publicado: (2020)

Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
por: Park, Joong-Won, et al.
Publicado: (2015)

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2022)

Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib
por: Labeur, Tim A., et al.
Publicado: (2019)

Hepatocellular adenoma in men: A nationwide assessment of pathology and correlation with clinical course
por: van Rosmalen, Belle V., et al.
Publicado: (2021)

Predicting microvascular invasion in hepatocellular carcinoma: A dual‐institution study on gadoxetate disodium‐enhanced MRI
por: Jiang, Hanyu, et al.
Publicado: (2022)

Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial
por: Kudo, Masatoshi, et al.
Publicado: (2020)

Preoperative evaluation of microvascular invasion with circulating tumour DNA in operable hepatocellular carcinoma
por: Wang, Dong, et al.
Publicado: (2020)

A multicentre retrospective analysis on growth of residual hepatocellular adenoma after resection
por: Klompenhouwer, Anne J., et al.
Publicado: (2020)

Ribociclib enhances infigratinib‐induced cancer cell differentiation and delays resistance in FGFR‐driven hepatocellular carcinoma
por: Prawira, Aldo, et al.
Publicado: (2020)

Alcohol‐related hepatocellular carcinoma is a heterogenous condition: Lessons from a latent class analysis
por: Costentin, Charlotte E., et al.
Publicado: (2022)

Hypomethylation of long interspersed nuclear element-1 promoter is associated with poor outcomes for curative resected hepatocellular carcinoma
por: Gao, Xu-dong, et al.
Publicado: (2014)

Interaction of FGF9 with FGFR3‐IIIb/IIIc, a putative driver of growth and aggressive behaviour of hepatocellular carcinoma
por: Paur, Jakob, et al.
Publicado: (2020)

Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis
por: Park, Joon Oh, et al.
Publicado: (2016)

Outcome of liver cancer patients with SARS‐CoV‐2 infection: An International, Multicentre, Cohort Study
por: Muñoz‐Martínez, Sergio, et al.
Publicado: (2022)

Multicentre, phase II study of gemcitabine and S‐1 in patients with advanced biliary tract cancer: TG1308 study
por: Chiang, Nai‐Jung, et al.
Publicado: (2020)

Rapid automated diagnosis of primary hepatic tumour by mass spectrometry and artificial intelligence
por: Giordano, Silvia, et al.
Publicado: (2020)

Nationwide treatment and outcomes of perihilar cholangiocarcinoma
por: van Keulen, Anne‐Marleen, et al.
Publicado: (2021)

Comparison of primary liver cancer mortality estimates from World Health Organization, global burden disease and global cancer observatory
por: Li, Chenxi, et al.
Publicado: (2022)

Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second‐line clinical trials
por: Tovoli, Francesco, et al.
Publicado: (2021)

DKK1 drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with anti‐DKK1 therapeutic DKN‐01
por: Jarman, Edward J., et al.
Publicado: (2022)

Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors
por: Shiina, Shuichiro, et al.
Publicado: (2012)

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma
por: Harding, James J., et al.
Publicado: (2021)

CT With Hepatic Arterioportography as a Pretreatment Examination for Hepatocellular Carcinoma Patients: A Randomized Controlled Trial
por: Ohki, Takamasa, et al.
Publicado: (2013)

Alpha‐fetoprotein‐adjusted‐to‐HCC‐size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma
por: Meischl, Tobias, et al.
Publicado: (2021)

Selective internal radiation therapy (SIRT) for hepatocellular carcinoma (HCC): informing clinical practice for multidisciplinary teams in England
por: Reeves, Helen L, et al.
Publicado: (2022)

Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
por: Chau, Ian, et al.
Publicado: (2018)

Recurrent Hepatocellular Carcinoma in an Adult With Alagille Syndrome Treated With Liver Resection Followed by Liver Transplantation: A Rare Case Report
por: Galvez, Daniel, et al.
Publicado: (2020)

Early hepatocellular carcinoma
por: Jin, So-Young, et al.
Publicado: (2011)

Percutaneous cryoablation for hepatocellular carcinoma
por: Song, Kyoung Doo
Publicado: (2016)

Infiltrative Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis Treated With a Single High-Dose Y90 Radioembolization and Subsequent Liver Transplantation Without a Recurrence
por: Dendy, Meaghan S., et al.
Publicado: (2017)

Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma
por: Murai, Hiroki, et al.
Publicado: (2023)

Exophytic combined hepatocellular carcinoma and cholangiocarcinoma
por: Noh, Sang Jae, et al.
Publicado: (2012)

β-catenin activated hepatocellular adenoma
por: Chu, Hyun Hee, et al.
Publicado: (2013)

Recent advances in the imaging of hepatocellular carcinoma
por: You, Myung-Won, et al.
Publicado: (2015)

Salford alcohol assertive outreach team: a new model for reducing alcohol-related admissions
por: Hughes, Neill R, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5df9fh7786g5i4fj7qgiol05gt